SCHEMBL10275329

SCHEMBL10275329

N#Cc1ccc(C2=NC(=O)n3nc(C(F)(F)F)c(-c4ccc(F)cc4F)c32)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARF6 P62330 3/20 0.37
AR P10275 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KIF11 P52732 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
GABRG2 P18507 4/20 0.33
GABRB3 P28472 4/20 0.33
GABRA5 P31644 4/20 0.33
GABRA3 P34903 4/20 0.33
GABRA1 P14867 3/20 0.33
GABRA2 P47869 2/20 0.33
KDM1A O60341 1/20 0.33
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRB2 P47870 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276100 0.87 KIF11 (0.39) ARPDE3BPDE3AKIF11NPSR1
SCHEMBL10275390 0.86 AR (0.37) ARPDE3BPDE3AGABRG2GABRB3
SCHEMBL10276098 0.84 KIF11 (0.35) ARPDE3BPDE3AKIF11KDM1A
SCHEMBL10275608 0.84 ADORA1 (0.42) ARPDE3BPDE3AGABRG2GABRB3
SCHEMBL10275425 0.84 AR (0.38) ARF6ARPDE3BPDE3AKIF11
SCHEMBL10275747 0.83 GABRG2 (0.36) ARPDE3BPDE3ACYP3A4CYP2C19
SCHEMBL10276213 0.82 KDM1A (0.37) ARF6ARPDE3BPDE3AGABRG2
SCHEMBL10275596 0.76 PGR (0.38) PDE3BPDE3AKIF11CYP3A4CYP2C19
SCHEMBL10276342 0.75 NPSR1 (0.44) KIF11NPSR1BRAFKDR
SCHEMBL10275213 0.74 APP (0.36) PDE3BPDE3ACYP3A4CYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 ARF6 3355/4885AR 3221/4885PDE3B 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.